Movers and SHAKERS
Complied with Nasdaq Minimum Bid Price Requirement
As of April 24, 2020, Noble Capital Markets research on Neovasc is published under ticker symbols (NVCN and NVCN:CA). The price target is in USD and based on ticker symbol NVCN. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target. Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Regained compliance with the minimum bid price. Neovasc regained compliance with Nasdaq with the minimum bid price requirement and will continue listing on Nasdaq. The shares gained 55% attributed to this news. The company is still required to maintain the minimum market value of US$35 million by June 8, 2021, to continue its listing.
Reducer Germany reimbursement is renewed. New examination and treatment methods (NUBs) Status 1 was renewed for 2021 under the German healthcare system. As Reducer is currently CE-marked in the European Union for the treatment of refractory angina, this highest priority designation is renewed every year and open doors to full reimbursement coverage for Reducer therapy ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.